Compare First Trust NASDAQ 100 Technology Index Fund (QTEC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ 100 Technology Index Fund vs Spyre Therapeutics Inc. Common Stock — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $303.09 (market cap $4.40B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and First Trust NASDAQ 100 Technology Index Fund is more actively traded (160,706 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ 100 Technology Index Fund for 40 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| QTEC | SYRE | |
|---|---|---|
Market Cap | $4.40B | $7.52B |
Volume | 160,706 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $340.28 | $108.92 |
52-Week Low | $207.03 | $22.18 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $324.27, down 0.59% on the day. The technical outlook is bullish based on moving averages, with key support at $321 and resistance at $335. Recent analysis highlights its equal-weighted exposure to the technology sector and better liquidity compared to peers.
The ETF offers broad tech exposure but faces sector-specific volatility risks. Upside potential hinges on technology sector performance, while downside risks include macroeconomic pressures on growth stocks. Investor sentiment remains mixed with a neutral oscillator reading.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
